Taysha Gene Therapies (TSHA) Construction in Progress (2021 - 2022)
Taysha Gene Therapies (TSHA) reported Construction in Progress of $59.0 million for Q3 2022, up 160662.94% on a YoY basis from N/an in Q3 2021, and up 1803.23% sequentially from $3.1 million in Q2 2022.
Taysha Gene Therapies (TSHA) Construction in Progress (2021 - 2022) Analysis & Trends
Taysha Gene Therapies (TSHA) has 2 years of Construction in Progress data on file, last reported at $59.0 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 137.45 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 59.00 Mn |
| Jun 30, 2022 | 3.10 Mn |
| Mar 31, 2022 | 50.40 Mn |
| Sep 30, 2021 | 36,700.00 |
| Jun 30, 2021 | 30.30 Mn |